Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin
Version of Record online: 25 JAN 2000
Copyright © 2000 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 73, Issue 1, pages 21–25, January 2000
How to Cite
Leithner, A., Schnack, B., Katterschafka, T., Wiltschke, C., Amann, G., Windhager, R., Kotz, R. and Zielinski, C. C. (2000), Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J. Surg. Oncol., 73: 21–25. doi: 10.1002/(SICI)1096-9098(200001)73:1<21::AID-JSO6>3.0.CO;2-G
- Issue online: 25 JAN 2000
- Version of Record online: 25 JAN 2000
- Manuscript Accepted: 24 SEP 1999
- aggressive fibromatosis;
- systemic therapy;
- nonsurgical treatment
Background and Objectives
Surgery is the main treatment for extra-abdominal desmoid tumors, but the results of further management remain uncertain. Therefore, a retrospective analysis was undertaken to evaluate the toxicity and efficacy of treatment with interferon-alpha (IFN-α) ± tretinoin in this setting.
Thirteen patients with extra-abdominal desmoid tumors and a median age of 32 years (range, 15–73) received IFN-α. Seven of these patients received a combination of IFN-α and tretinoin in order to test further enhancement.
After a mean observation period of 27 ± 15 months (mean ± standard deviation) under treatment with IFN-α ± tretinoin, local control was seen in 11 of 13 patients (85%). Seven patients had no evidence of disease at a mean disease-free interval of 22 ± 18 months; in two patients progressive disease occurred after only 7 and 9 months, respectively, of observation. In another four patients, progression of the desmoid tumor was stabilized.
The data of this retrospective, nonrandomized study on therapy with IFN-α ± tretinoin suggest that such treatment may be effective in prolonging the disease-free interval of patients after intralesional or marginal surgery. Because of the encouraging response rate, this regimen appears to be another nonsurgical treatment alternative. J. Surg. Oncol. 2000;73:21–25. © 2000 Wiley-Liss, Inc.